Cajal Neuroscience Inc. announced that it has received $95.7 million in funding from The Column Group LLC, Lux Capital Management, LLC, Two Sigma Ventures, LP, Bristol-Myers Squibb Company, Alexandria Venture Investments, LLC, Dolby Family Ventures, L.P and other investors

On November 29, 2022, Cajal Neuroscience Inc. closed the transaction. The round of funding co-led by new investor The Column Group LLC, and Lux Capital Management, LLC. The transaction also involved participation from new investors Two Sigma Ventures, LP, Bristol-Myers Squibb Company, Alexandria Venture Investments, LLC, Evotec SE, Dolby Family Ventures, L.P, and other investors.